小分子抑制微RNA-210重新编程致癌性低毒循环
Matthew G Costales1, Christopher L Haga1, Sai Pradeep Velagapudi1
1Department of Chemistry, ‡Department of Molecular Therapeutics, and §Department of Neuroscience, The Scripps Research Institute , 130 Scripps Way, Jupiter, Florida 33458, United States.
Journal of the American Chemical Society
|February 28, 2017
概括
一种新的小分子Targapremir-210可以选择性地向microRNA-210 (miR-210) 前体. 这抑制了癌细胞的生长,并特别在缺氧三阴性乳腺癌中触发了细胞亡.
科学领域:
- 分子生物学
- 癌症研究
- 有关RNA疗法
背景情况:
- 低氧对癌症转移和侵袭至关重要.
- 微RNA-210 (miR-210) 调节低氧诱导因子 (HIF),影响癌症的进展.
- 向RNA为癌症治疗提供了一个新的前沿, 但研究RNA和小分子相互作用的方法是有限的.
研究的目的:
- 确定和描述一个小分子抑制剂的miR-210.
- 研究小分子的作用机制和细胞选择性.
- 评估小分子对低氧三阴性乳腺癌的治疗潜力.
主要方法:
- 用化学交叉链接和通过拉下隔离 (Chem-CLIP) 来研究小分子-RNA相互作用.
- 小分子Targapremir-210的设计是为了结合miR-210的前体.
- 实验室和体内低氧三阴性乳腺癌模型被使用.
主要成果:
- 塔尔加佩米尔-210可选择性地与miR-210前体结合,从而抑制成熟的miR-210产生.
- 这导致GPD1L的减压,HIF-1α的降低,以及缺氧下癌细胞的亡.
- 在老鼠异种移植模型中,Targapremir-210在抑制瘤生长方面表现出有效性.
- 根据表达水平,Targapremir-210具有选择性识别RNA的能力.
结论:
- 小分子可以被设计为选择性向特定的RNA,从而提供治疗效益.
- 在低氧三阴性乳腺癌中,targapremir-210是一种有前途的治疗策略.
- 这项研究定义了在转录组内识别可用药的RNA点的新规则.
相关概念视频
MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs
24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Experimental RNAi
8.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K


